Skip to content

Dexmedetomidine for sedation during bronchoscopy.

Nebulised dexmedetomidine inhalation versus placebo as a premedication for flexible bronchoscopy : A randomised controlled trial.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044389
Enrollment
90
Registered
2022-07-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C348- Malignant neoplasm of overlappingsites of bronchus and lung Health Condition 2: J98- Other respiratory disorders

Interventions

Intervention1: Nebulised dexmedetomidine: At the rate of 2 μg / kg body weight, given 20 minutes before bronchoscopy for 4 minutes. Control Intervention1: Normal saline: Nebulised normal saline as pl

Sponsors

Pt BDS university of health sciences Rohtak
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Able to and willing to provide informed consent

Exclusion criteria

Exclusion criteria: 1) Clinically important coronary atherosclerotic heart disease, history of stroke or transient ischemic attack 2) Known case of psychiatric illness. 3) Immediate life-threatening comorbidities 4) Requiring NIV during bronchoscopy for other indications

Design outcomes

Primary

MeasureTime frame
Severity of cough post flexible bronchoscopy as mild moderate and severe according to the episodes of coughTimepoint: mild, 1â??2; moderate, 3â??4; and severe, 5 or more to be assessed at the end of bronchoscopy procedure.

Secondary

MeasureTime frame
Adverse events if anyTimepoint: To be assessed at anytime during and after the procedure.;Operator discomfort : 0% to 100% from none to maximumTimepoint: to be assessed at 10 minutes after the end of bronchoscopy procedure.;Patients discomfort : 0% to 100% from none to maximumTimepoint: To be Assessed at 10 minutes after the end of bronchoscopy procedure.

Countries

India

Contacts

Public ContactJahanvi Grover

Pt BDS university of health sciences , Rohtak

ga.ps.complete@gmail.com8437013094

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026